What is known and objective: The FDA has provided recommendations for aripiprazole use in CYP2D6 poor metabolizers (PMs); however, PMs make up <1% of the Asian population and no recommendation has been provided for intermediate metabolizers (IMs), who comprise a considerable proportion of the Asian population (64%-70% occurrence of CYP2D6*10). This study aimed to investigate the characteristics of aripiprazole metabolism in IMs and other phenotypes by conducting the first meta-analysis of the association among CYP2D6 phenotypes and aripiprazole pharmacokinetics (PK).
| WHAT IS K NOWN AND OBJEC TIVE
Aripiprazole is an atypical antipsychotic used in the management of schizophrenia, bipolar disorder, major depressive disorder, irritability associated with autism disorder and Tourette's disorder. 1 It has been widely used for the treatment of schizophrenia in many countries worldwide, including the European Union, the United States, Korea, Japan and China. [2] [3] [4] [5] [6] The metabolism and elimination of aripiprazole are largely mediated through two enzymes, CYP2D6 and CYP3A4. 1 Drug activity is derived primarily from the parent drug aripiprazole and to a lesser extent from its main metabolite, dehydroaripiprazole.
7,8
CYP2D6 is a member of the cytochrome P450 gene superfamily.
Owing to its highly polymorphic nature and major contribution to the metabolism and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively studied drug-metabolizing enzymes. 9 The relationship between CYP2D6 genotype and phenotype has been intensively studied over the past decade; various methods have been used to predict CYP2D6 phenotype based on its genotype. [10] [11] [12] Establishing a unified standard for phenotypic assignment based on genotypic data has been the goal of many researchers in this field. 13 As is shown in Table 1 , subjects can be classified into four phenotypes 10 or ultra-rapid metabolizers (UMs, carrying two functional alleles).
To date, an increasing number of studies have suggested that CYP2D6 gene polymorphism/phenotype has a significant impact on aripiprazole pharmacokinetics (PK). The FDA drug label states that PMs are exposed to higher concentrations of aripiprazole and lower concentrations of dehydroaripiprazole and that the exposure to total drug moieties is 60% higher than in EMs. 11 Thus, it has been recommended by the FDA drug label and Clinical Pharmacogenetics Implementation Consortium guidelines that CYP2D6 PMs be administered half of the usual dose of aripiprazole. The aim of this study was to confirm the need for aripiprazole dose adjustment in CYP2D6 IMs and to analyse differences in aripiprazole PK among CYP2D6 phenotypes.
| ME THODS

| Data sources, search strategy and selection criteria
All studies examining the relationship between CYP2D6 and aripiprazole PK were eligible for inclusion in our study, and no restrictions were placed on language or publication status (published, in press or in progress). We searched the Embase, PubMed, Cochrane 
| Data collection and quality assessment
An electronic data abstraction form was used to record basic data, including the first author's name, publication year, number of subjects, ethnicity, subject status (healthy individuals or patients with schizophrenia), CYP2D6 genotypes, drug usage, outcomes and major conclusions. Outcome data, including aripiprazole C max in single-dose studies and aripiprazole concentration/dose ratio, dehydroaripiprazole/dose ratio and aripiprazole + dehydroaripiprazole concentration/dose in aripiprazole multiple-dose studies, were also collected. Outcome-related data were collected separately for CYP2D6 UMs, EMs, IMs and PMs.
Original data were collected in the form of "Mean, SD, n," except for four studies, [18] [19] [20] [21] in which the original data were presented in the form of "median, range, n." For these, we estimated the mean and variance based on the median, range and size of the sample using the method introduced by Hozo et al.
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We used the Newcastle-Ottawa Scale (NOS) to assess the methodological quality of the eligible trails; this method is comprehensive and has been partially validated for evaluating the quality of observational studies in meta-analysis. 23 The NOS assigns up to a maximum of nine points for the least risk of bias in three domains: (a) selection of study groups (four points); (b) comparability of groups (two points); and (c) ascertainment of exposure and outcomes (three points) for case-control and cohort studies, respectively. 24 NOS questions covering all three domains were answered for all of the enrolled studies, and their methodological quality was assessed. A greater number of points indicate a higher quality of study design.
| Statistical analysis
Statistical analyses were performed using STATA software (version 
| RE SULTS AND D ISCUSS I ON
| Study characteristics
The results of the literature screen process are presented in Figure 1 .
We identified 259 articles published through February 2018 following a comprehensive search of the Embase, PubMed, Cochrane
Library and Web of Science databases. After removing duplicates, we reviewed the remaining 185 articles in the form of title and abstract; 121 citations were excluded after the title and abstract screen.
Subsequently, 55 articles were excluded following a full-text screen, leaving 10 articles eligible for meta-analysis. 10, 12, [18] [19] [20] [21] [29] [30] [31] [32] The general characteristics of the included studies are summarized in Table 1 .
As shown in Table 1 , a total of 649 subjects were included in our meta-analysis, 215 of whom were healthy individuals, while the remainder consisted of patients with schizophrenia. For healthy individuals, the study design involved the administration of a single dose of aripiprazole, while patients were administered multiple doses.
The ethnicities included Japanese, Spanish, Dutch, Belgian and
Norwegian. CYP2D6 phenotypes were re-classified according to a unified standard prior to subject inclusion, 10,33 regardless of the standards used in the original studies. The unified classification standard of the four phenotypes (UM, EM, IM and PM) is described in Table 1 , and the actual variants used to assign CYP2D6 genotypes are shown in Table 2 . Based on NOS quality analysis, six studies received a score of 7 and four studies received a score of 6. Overall, the quality of the included studies was suitable for enrolment in the meta-analysis.
| Meta-analyses results
In total, three outcomes related to aripiprazole PK were analysed for their association with the CYP2D6 phenotype, including (dose- and related data) are detailed below and summarized in Table 3 .
As the study by Azuma et al 29 consisted of two groups of healthy subjects whose data were provided separately in the original article, the study is presented as "group 1" and "group 2" in all of the figures. Figure 2A shows the forest plot for the comparison between UMs and EMs including 349 subjects from five studies. The random-effects model was adopted because of heterogeneity (I 2 = 54.9%, P Q = 0.06 < 0.5). The serum level of aripiprazole was significantly lower in UMs than in EMs (UM vs EM pooled SMD: −0.643; 95% CI: −1.085 to −0.201, P < 0.01; Figure 2 ).
| (Dose-adjusted) aripiprazole serum levels and CYP2D6 phenotype
| UMs vs EMs
These results demonstrate that CYP2D6 UMs have a lower dose-adjusted aripiprazole serum level than EMs and that this difference is significant.
| EMs vs IMs
The forest plot for the 513 subjects from nine studies examined in this analysis is shown in Figure 2B . The random-effects model was adopted because of heterogeneity (I 2 = 58.5%, P Q = 0.01 < 0.5). The serum level of aripiprazole was significantly lower in EMs than in IMs (EM vs IM pooled SMD: −0.383; 95% CI: −0.735 to −0.031, P = 0.03; Figure 2B ). We next conducted a sensitivity analysis of heterogeneity;
when the study by van der Weide and van der Weide 21 was omitted, the observed heterogeneity across the studies was clearly reduced EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra-rapid metabolizer. *P < 0.05. **P < 0.01. Figure 3A shows the Forest plot for the comparison between UMs and EMs including 322 subjects from five studies. The fixed-effects model was adopted as no significant heterogeneity was detected across the studies (I 2 = 41.6%, P Q = 0.14 > 0.5). The serum level of aripiprazole was significantly lower in UMs than in EMs (UM vs EM pooled SMD: −0.651; 95% CI: −0.927 to −0.376, P = 0.000; Figure 3A ).
| IMs vs PMs
| UMs vs EMs
These results demonstrate that CYP2D6 UMs have a lower doseadjusted aripiprazole plus dehydroaripiprazole serum level than EMs and that this difference is significant.
| EMs vs IMs
The Forest plot for the 401 subjects from six studies examined in this analysis is shown in Figure 3B . The random-effects model was adopted because of heterogeneity (I 2 = 67.7%, P Q = 0.01 < 0.5). The serum level of aripiprazole plus dehydroaripiprazole was lower in EMs than in IMs; however, the difference was not significant (EM vs IM pooled SMD: −0.285; 95% CI: −0.724 to −0.154, P = 0.20; Figure 3B ).
These results demonstrate that CYP2D6 EMs have a slightly lower aripiprazole serum level than IMs, but that the difference is not significant.
| IMs vs PMs
The Forest plot for the comparison between IMs and PMs including 115 subjects from three studies is shown in Figure 3C . The fixed-effects model was adopted as no significant heterogeneity was detected across the studies (I 2 = 0.0%, P Q = 0.71 > 0.5). Overall, the serum level of aripiprazole was slightly lower in IMs than in PMs; however, the difference was not significant (IM vs PM pooled SMD: −0.302; 95% CI: −0.810 to 0.205, P = 0.24; Figure 3C ). This result indicates that there is no significant difference between CYP2D6
IMs and PMs in terms of aripiprazole plus dehydroaripiprazole level.
The sum serum levels of these two active molecules were similar in IMs and PMs.
3.5 | (Dose-adjusted) dehydroaripiprazole serum levels and CYP2D6 phenotype
| UMs vs EMs
The Forest plot for the comparison between UMs and EMs including 322 subjects from five studies is shown in Figure 4A . The randomeffects model was adopted because of heterogeneity (I 2 = 50.8%, P Q = 0.09 < 0.5). No significant difference was observed between the dehydroaripiprazole serum level in UMs and EMs (UM vs EM pooled SMD: −0.236; 95% CI: −0.651 to 0.179, P < 0.01; Figure 4A ).
| EMs vs IMs
The Forest plot for the 401 subjects from six studies examined in this analysis is shown in Figure 4B . The random-effects model was adopted because of heterogeneity (I 2 = 60.0%, P Q = 0.03 < 0.5). The serum level of aripiprazole was slightly lower in EMs than in IMs; however, the difference was not significant (EM vs IM pooled SMD:
−0.236; 95% CI: −0.651 to 0.179, P = 0.27; Figure 4B ).
| IMs vs PMs
The Forest plot for the 115 subjects from three studies examined in this analysis is shown in Figure 4C . The fixed-effects model was adopted because no significant heterogeneity was detected across the studies (I 2 = 31.0%, P Q = 0.24 > 0.5). The serum level of aripiprazole was significantly higher in IMs than in PMs (IM vs PM pooled SMD: 0.803; 95% CI: 0.277-1.328, P < 0.01; Figure 4C ). These results indicate that CYP2D6 IMs have a significantly higher serum level of dehydroaripiprazole than PMs following multiple doses of aripiprazole.
| Analysis of publication bias
The publication bias for dose-adjusted aripiprazole serum levels and CYP2D6 phenotype (EMs vs IMs) was analysed using the Begg's funnel plot and the Egger's and Begg's tests. Publication bias was analysed only for this meta-analysis because it was the only one that included more than seven studies.
No obvious publication bias was observed for the nine studies.
The funnel plot is shown in Figure 5 ; the results of the Egger's test In addition, the results demonstrate that aripiprazole serum level and the sum aripiprazole + dehydroaripiprazole serum level exhibit the same trend in different metabolizers: UMs < EMs < IMs < PMs.
This is consistent with the predicted metabolic activity of the CYP2D6 enzyme in the four phenotypes. The enzyme activity conforms to the trend: UMs > EMs > IMs > PMs.
| LI M ITATI O N S
Two potential limitations should be considered when interpreting the results of the present study. First, our meta-analyses included and S2). Second, the number of subjects included was low, and thus, our results might only reflect small-study effects. Further clinical studies with larger sample sizes are necessary to verify the conclusions of this study and provide more detailed recommendations.
| CON CLUS IONS
Aripiprazole serum concentration differed significantly between IMs and EMs, but not between IMs and PMs. Whether this has clinical significance requires further evaluation by randomized controlled trials.
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